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The global health emergency generated by coronavirus disease 2019 (COVID-19) has prompted 
the search for preventive and therapeutic treatments for its pathogen, the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). There are many potential targets for drug 
discovery and development to tackle this disease. One of these targets is the main protease, 
Mpro or 3CLpro, which is highly conserved among coronaviruses. 3CLpro is an essential player 
in the viral replication cycle, processing the large viral polyproteins and rendering the 
individual proteins functional. We report a biophysical characterization of the structural 
stability and the catalytic activity of 3CLpro from SARS-CoV-2, from which a suitable 
experimental in vitro molecular screening procedure has been designed. By screening of a 
small chemical library consisting of about 150 compounds, the natural product quercetin was 
identified as reasonably potent inhibitor of SARS-CoV-2 3CLpro (Ki  7 µM). Quercetin could be 
shown to interact with 3CLpro using biophysical techniques and bind to the active site in 
molecular simulations. Quercetin, with well-known pharmacokinetic and ADMET properties, 
can be considered as a good candidate for further optimization and development, or 



























December 2019 was the starting point for a global pandemic, caused by a newly identified 
coronavirus, SARS-CoV-2, rising to dramatic numbers of infections and deaths worldwide[1, 2]. 
Much effort and many resources have been devoted to combat this health emergency on 
many fronts: 1) better diagnosis and patient management[3]; 2) improving protective and 
palliative care[4]; 3) reducing damage in the different organs affected by the virus and 
minimizing collateral harmful effects of the immune response[5]; and 4) developing preventive 
vaccines and therapeutic treatments[6], to mention the more relevant. In addition, very strict 
and severe social and economic measures, with the potential danger of causing a profound 
global crisis, have been taken[7]. In this context, even if an effective vaccine is promisingly 
close to becoming available, drugs are needed for infected people[8]. From experience with 
other pathogens, we have learnt that the best therapeutic strategy consists in administrating a 
combination of several drugs acting through different mechanisms, in order to minimize the 
probability of drug resistance appearance[9]. At the same time, cost-efficient drugs (if possible, 
developed by repositioning or repurposing known drugs) are urgently needed to reaching all 
the population[10]. 
The SARS-CoV-2 genome is 82% identical to that of SARS-CoV, the causative virus of the 2002 
coronavirus outbreak[11]. The genomic differences are reflected in a different infectivity and 
mortality rates for SARS-CoV-2[12]. Among all the potential protein targets within 
coronaviruses, the main protease (Mpro, or 3C-like protease, 3CLpro) stands out as associated 
to a highly conserved gene (96% sequence identity between the SARS-CoV-2 and SARS-CoV), 
making 3CLpro a good target for developing effective drugs against SARS-CoV-2 (and other 
future coronavirus variants)[13, 14]. Together with PLpro, 3CLpro is responsible for the 
processing of the viral polyproteins synthesized from the viral RNA after infection, rendering 
the individual viral proteins active and functional[15]. Remarkably, 3CLpro must process at 
least 11 cleavage sites on polyprotein 1ab (replicase 1ab), most of them sharing a common 
cleavage sequence LQ(S/A/G), quite unusual for human proteases[16]. Therefore, molecules 
able to inhibit SARS-CoV-2 3CLpro in a specific manner would hinder viral replication and 
represent appropriate candidates to develop low-toxicity drugs against this devastating 
pathogen[17]. 
Searching for drugs against a protein target always benefits from a comprehensive structural 
and functional characterization[18]. Experimental and computational knowledge gathered  
along this process is instrumental for identifying weak points and key interaction sites in the 
target, and developing suitable screening procedures for finding molecules interfering with or 













features of SARS-CoV-2 3CLpro by employing biophysical techniques (spectroscopy and 
calorimetry), and we have implemented a fast in vitro screening procedure based on 3CLpro 
hydrolytic activity using a Förster resonance energy transfer (FRET) substrate, which allows the 
ready identification of small molecules blocking the enzymatic activity of 3CLpro. Starting from 
a small chemical library consisting of about 150 compounds, collected from successful 
screening programs previously carried out in our laboratory, a natural compound was 
identified as an inhibitor of SARS-CoV-2 3CLpro with enough potency (inhibition constant Ki  7 
µM) to be considered a good candidate for further optimization and development. Quercetin, 
with known pharmacokinetic and ADMET properties, exhibits anti-oxidant, anti-allergic, anti-
inflammatory, and anti-proliferative indications, and can be directed for drug repositioning. 
 
MATERIALS & METHODS 
Protein expression and purification 
A pET22b plasmid containing the SARS-CoV-2 His-tagged 3CLPRO sequence was transformed 
into BL21 (DE3) Gold E. coli strain. Bacterial cultures were grown in 250 mL of LB/ampicillin 
(100 μg/mL) media at 37 °C overnight with gentle shaking. Then, 4 L of LB/ampicillin (100 
μg/mL) were inoculated and incubated under the same conditions until reaching OD = 0.6 at a 
wavelength of 600nm. Protein expression was induced with 1 mM isopropyl 1-thio-β-D-
galactopyranoside (IPTG) at 18 °C for 5 h. Cells were harvested by centrifugation at 4 C for 10 
min at 10000 rpm (using a Beckman Coulter Avanti J-26 XP Centrifuge) and then resuspended 
in lysis buffer (sodium phosphate 50 mM, pH 8, sodium chloride 500 mM). Cell rupture was 
achieved by sonication (using a Sonics Vibra-Cell Ultrasonic Liquid Processor) in ice, and 20 
U/mL of benzonase (Merck-Millipore) were added to remove nucleic acids. To remove cellular 
debris, the extract was centrifuged at 4 °C for 30 min at 20000 rpm, and filtered through a 0.45 
μm-pore membrane. After increasing imidazole concentration up to 10 mM, the protein was 
purified using immobilized metal ion affinity chromatography (IMAC) in a ÄKTA FPLC System 
(GE Healthcare Life Sciences) using a cobalt HiTrap TALON column (GE-Healthcare Life 
Sciences), eluting in an imidazole 10-250 mM gradient. Purity was checked by SDS-PAGE, and 
pure protein fractions were dialyzed to remove imidazole and reach the protein storage 
condition (sodium phosphate 50 mM, pH 8, sodium chloride 150 mM). The identity of the 
protein was assessed by mass spectrometry (LC-ESI-MS/MS). Potential DNA contamination was 
assessed by determining the UV absorption 260/280 ratio. An extinction coefficient of 32890 
M−1 cm−1 at 280 nm was employed for quantification. When needed, buffer exchange was 














Circular dichroism and fluorescence spectroscopy 
Circular dichroism (CD) spectra were recorded in a Chirascan spectropolarimeter (Applied 
Photophysics) at 25 °C. Far-UV spectrum was recorded at wavelengths between 190 and 260 
nm in a 0.1 cm path-length cuvette. Near-UV spectrum was recorded at wavelengths between 
250 and 310 nm in a 1-cm path-length cuvette. Protein concentration was 10 μM in all cases. 
Fluorescence measurements were performed in a Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies), monitoring the intrinsic tryptophan fluorescence of 
a protein solution at 2 μM concentration. An excitation wavelength of 290 nm was used, with 
excitation and emission bandwidths of 5 nm, and recording fluorescence emission between 
300 and 400 nm. All spectroscopic measurements were made in sodium phosphate 50 mM, pH 
8. 
Thermal denaturations were monitored by CD and fluorescence, employing a protein 
concentration of 10 M and 2 M, respectively, and performing thermal scans with a scanning 
rate of 60 C/h. 
 
Dynamic light scattering 
Hydrodynamic radius of SARS-CoV-2 3CLpro was measured at different pH values for 
estimating the size of the oligomeric native state in a DynaPro NanoStar equipment (Wyatt 
Technology), employing a protein concentration of 3 M at pH 5, 7 and 8. 
 
Size-exclusion chromatography 
Self-association state of SARS-CoV-2 3CLpro was assessed employing an ÄKTA FPLC (GE 
Healthcare) using a Superdex Increase 75 10/30 chromatographic column, at pH 8 and 150 mM 
NaCl. 
 
Differential scanning calorimetry 
Thermal stability of SARS-CoV-2 3CLpro was assessed by temperature unfolding transitions 
monitored by high-precision differential scanning calorimetry (DSC). The partial molar heat 
capacity of the protein in solution was measured as a function of temperature in an Auto-
PEAQ-DSC (MicroCal, Malvern-Panalytical). Experiments were performed with a protein 
solution at a concentration of 14 M in buffer, and scanning from 15 to 95 C at a rate of 60 
C/h. Different buffers were employed to get protein stability information under different 















Model-free calorimetric analysis 
The first approach in DSC experimental analysis consists of applying a model-free data analysis 
for discriminating between different possibilities: two-state unfolding, non-two-state 
unfolding, and oligomer unfolding of the protein. From the thermogram (excess molar heat 
capacity of the protein as a function of the temperature, <CP(T)>), the calorimetric unfolding 
enthalpy, Hcal, the unfolding temperature, Tm, and the maximal unfolding heat capacity, CP,max, 





         (1) 
From the ratio HvH/Hcal different possibilities may arise: 1) if HvH/Hcal = 1, the thermogram 
would reflect a single transition and the protein unfolds according to a two-state model (i.e., 
the protein contains a single energetic domain); 2) if HvH/Hcal < 1, the thermogram would 
reflect at least two (partially) overlapping transitions and the protein unfolds according to a 
non-two-state model (i.e., the protein contains at least two domains which unfold in an 
independent manner); and 3) if HvH/Hcal > 1, the thermogram would reflect an unfolding 
transition coupled to subunit dissociation (i.e., the protein is oligomeric and unfolds into 
monomers). 
In the case of SARS-CoV-2 3CLpro, the thermograms under the different conditions assayed 
showed that HvH/Hcal > 1 and, therefore, the protein is not monomeric and dissociates upon 
thermal unfolding. In fact, according to the crystallographic structure of the unliganded 
species, the protein is dimeric in its native state, although it has been reported that SARS-CoV-
1 3CLpro can populate tetramers and octamers. 
 
Cooperative homo-oligomeric protein unfolding into isolated unfolded monomers 
The conformational equilibrium is governed by the equilibrium constant, KU: 
𝑁𝑛 ↔ 𝑛𝑈,       𝐾𝑈 =
[𝑈]𝑛
[𝑁𝑛]
        (2) 
where Nn is the oligomeric native state constituted of n monomeric subunits, and U is the 
unfolded state of each identical monomeric subunit. The total protein concentration can be 
expressed (per monomer) as: 
[𝑃]𝑇 = 𝑛[𝑁𝑛] + [𝑈] =
𝑛
𝐾𝑈
[𝑈]𝑛 + [𝑈]       (3) 


























Given the equilibrium constant and the total protein concentration, Eq. 3 can be solved 
numerically for the unknown [U], and the molar fraction of both protein species can be 
calculated at any temperature, from which the excess average molar unfolding enthalpy, 
<H>(T) can be determined: 
〈∆𝐻〉(𝑇) = 𝐹𝑈(𝑇)∆𝐻𝑈(𝑇)        (5) 
where HU is the enthalpy of the unfolded state, considering that of the native state as a 
reference. The temperature derivative of the excess molar unfolding enthalpy is the excess 









      (6) 
taking into account the temperature dependence of the different magnitudes: 
∆𝐻𝑈(𝑇) = ∆𝐻𝑈(𝑇0) + ∆𝐶𝑃,𝑈(𝑇 − 𝑇0)









∆𝐺𝑈(𝑇) = ∆𝐻𝑈(𝑇) − 𝑇∆𝑆𝑈(𝑇)
𝐾𝑈 = 𝑒
−𝑛∆𝐺𝑈(𝑇)/𝑅𝑇
    (7) 
where SU, GU and CP,U are the entropy, the Gibbs energy and the heat capacity of the 
unfolded state (taking the native state as a reference), respectively, and T0 is an appropriate 
reference temperature. In this case, T0, is the temperature at which the unfolding Gibbs energy 
is zero, and does not coincide with the temperature for maximal heat capacity, Tmax, nor with 
the temperature for half denaturation, T1/2 (i.e., the temperature at which FU = 0.5, or median 
temperature in the thermogram). This model particularized to n = 1 corresponds to the two-
state model, for which T0 is the apparent unfolding temperature, Tm, which is very close to 
both Tmax and T1/2. 
For a spectroscopically monitored unfolding of a homo-oligomeric protein, the procedure is 
similar, but the final observable quantity is the spectroscopic signal, S(T), which can be 
calculated as: 
𝑆(𝑇) = 𝐹𝑁(𝑇)𝑆𝑁(𝑇) + 𝐹𝑈(𝑇)𝑆𝑈(𝑇)       (8) 
where SN(T) and SU(T) are the intrinsic spectroscopic signal values for the native and unfolded 
protein states, and can be considered linear functions of the temperature: 
𝑆𝑁(𝑇) = 𝐴𝑁 + 𝐵𝑁𝑇
𝑆𝑈(𝑇) = 𝐴𝑈 + 𝐵𝑈𝑇
         (9) 
 
Proteolytic activity assay 
In vitro catalytic activity of 3CLpro was determined using a fluorescence resonance energy 
transfer (FRET) cleavage continuous assay with the peptide substrate 













final concentration in sodium phosphate 50 mM, NaCl 150 mM, at pH 8, and the enzymatic 
reaction was initiated by adding the substrate at 20 M final concentration, in a final volume 
of 100 L. Fluorescence was continuously measured in a FluoDia T70 microplate reader 
(Photon Technology International) for 20 min (excitation wavelength, 380 nm; emission 
wavelength, 500 nm). Enzyme activity was quantified as the initial slope of the time evolution 
curve of the fluorescence signal. The slope ratio between the activity in the presence and 
absence of a given compound provides the percentage of inhibition. For comparison, the 
hydrolytic activity was also measured at different pH values. The Michaelis-Menten constant, 
Km, and the catalytic rate constant or turnover number, kcat, were estimated by measuring the 
initial enzymatic rate at different substrate concentrations at fixed 0.2 enzyme concentration 
and applying non-linear regression data analysis. 
 
Activity-based screening 
Screening of a small chemical library was performed based on the catalytic activity continuous 
FRET assay. In a 96-well microplate, enzyme at 1 M final concentration was incubated in the 
presence of chemical compounds (at 125 μM final concentration) solubilized previously at 5 
mM concentration in DMSO. The final concentration of DMSO was 2.5% v/v. The same amount 
of DMSO was added to control wells (no compounds added). Several hits were identified as 
those compounds reducing the enzymatic activity below a threshold (average enzymatic 
activity of controls minus twice their standard deviation). In order to determine the inhibition 
constants of the selected compounds, 2-fold serial dilutions of each compound were tested 
(ranging from 0 to 125 μM) under the same conditions described above. 
 
Inhibition assay 
To assess the in vitro inhibition potency of the selected compounds, the inhibition constants 
were estimated from the experimental curves. Inhibition curves were obtained by measuring 
the enzyme activity as a function of compound concentration: monitoring the substrate 
fluorescence emission as a function of time, fixing the enzyme concentration at 2 µM, the 
substrate concentration at 20 µM, and varying the compound concentration from 0 to 125 µM, 
while maintaining constant the percentage of DMSO. The enzymatic activity was quantitated 
as the initial slope of the substrate fluorescence emission time curve, and was plotted as a 
function of compound concentration. Non-linear regression analysis employing a simple 
inhibition model allowed us to estimate the apparent inhibition constant for both compounds, 
































        (10) 
where v is the initial slope of the enzymatic activity trace at a (free) compound concentration 
[I], Km is the Michaelis-Menten constant for the enzyme-substrate interaction, [S] is the 
substrate concentration, and Ki
app is the apparent inhibition constant for the compound. If the 
inhibitor acts through a purely competitive mechanism, the previous equation can be 

















       (11) 
where Ki is the intrinsic (i.e., substrate concentration-independent) inhibition constant.  
 
Thermal shift assay 
For the thermal shift assay (TSA), SYPRO Orange (Thermo Fisher Scientific) was employed as an 
extrinsic fluorescent probe for reporting protein unfolding. A reaction mixture containing 
3CLpro at 1 µM of final concentration in sodium phosphate 50 mM, pH 8, and SYPRO Orange at 
a final concentration of 5X, was freshly prepared and dispensed into 96-well microplates (96-
well PCR plate, non-skirted, from 4titude) at a final volume of 100 μL. Compound from a 5 mM 
stock solution in pure DMSO were added to the mixture of protein and fluorescence probe to a 
final concentration of 250 μM each. Controls were considered by adding the same volume of 
100% DMSO instead of any compound. Unfolding curves were registered from 25 °C to 99 °C at 
a 1 °C/min scan rate in a Stratagene Mx3005P qPCR real-time thermal cycler (Agilent 
Technologies). Thermal denaturation was followed by fluorescence emission of the fluorescent 
probe, using 492 and 610 nm as excitation and emission wavelength filters, respectively. The 
apparent midpoint unfolding temperature, Tm, was calculated in each well as the temperature 
of maximum slope (i.e., the inflection point), and compared to the controls. To assess the 
concentration dependence of the stability change induced by the selected compound, 2-fold 
serial dilutions (ranging from 0 to 125 μM) for each compound were assayed by following the 
same protocol described above. 
 
Isothermal titration calorimetry 
The interaction between the compound and 3CLpro was further assessed by isothermal 
titration calorimetry. Calorimetric titrations were performed using a high precision Auto-
iTC200 calorimeter (MicroCal, Malvern-Panalytical). Protein at 15 M and compound at 150 













Compound was titrated into protein solution by performing 19 injections of 2 µL each, and 
mixed using a stirring speed of 750 rpm, maintaining a spacing between injections of 150 s, 
and applying a reference power of 10 cal/s. The association constant, Ka, the binding 
enthalpy, ΔH, and the binding stoichiometry, N, were estimated through non-linear least 
squares regression analysis of the data, by using a model considering a single ligand binding 
site, implemented in Origin 7.0 (OriginLab). The dissociation constant, Kd, the binding Gibbs 




Molecular docking was performed by using the simulation software AutoDock Vina[23] and the 
supporting suite AutoDock Tools[24]. The structure of 3CLpro was extracted from the entries 
6Y2E and 6Y2F[22] of the Protein Data Bank (PDB), which contain the crystallographic 
conformation of the protein in unliganded form and with an α-ketoamide inhibitor bound in 
the active site, respectively. The protein structures were considered in all cases free from any 
ligand and water molecules. A few missing residues in the entry 6Y2F were reconstructed in 
silico, and the structure of quercetin was also built by using the molecular editor Avogadro[25]. 
A blind search was carried out on the whole protein surface, by considering a volume of size 50 
Å × 60 Å × 60 Å. Extensive sampling was performed in all cases, using an exhaustiveness 16 
times larger than the value normally recommended[26]. 
 
RESULTS 
SARS-CoV-2 3CLpro is properly folded 
Recombinant 3CLpro was expressed in E. coli at sufficiently high yield for initiating a 
biophysical characterization and an activity-based molecular screening (Figure S1). The far-UV 
circular dichroism (CD) spectrum showed negative bands around 208 and 222 nm, typical of 
proteins with -helical and -sheet content (Figure 1A), in agreement with the crystallographic 
structure[22]. The near-UV CD spectrum indicated aromatic residues, especially tryptophans, 
are enclosed within an asymmetric environment (Figure 1B). The fluorescence spectrum 
monitoring the intrinsic emission of the tryptophans (there are three tryptophan residues, two 
located in the -helical domain and one in the -sheet domain) showed a maximum around 
330, confirming that some of them are partially exposed to the solvent (Figure 1C). These 















SARS-CoV-2 3CLpro self-associates 
3CLpro from other coronaviruses (SARS-CoV and MERS) dimerizes, and such dimerization is 
known to be essential for the enzymatic activity; even higher-level oligomerization structures 
(tetramers and octamers) have been reported[27]. Among other experimental techniques 
providing information about protein oligomerization (such as analytical ultracentrifugation and 
gel filtration chromatography), thermal denaturation monitored by spectroscopy or 
calorimetry  can be used to detect the self-association of proteins, since the thermal unfolding 
of monomeric and oligomeric proteins show markedly different features[28]. 
Thermal unfolding of 3CLpro followed by far-UV CD showed a single transition with an 
apparent unfolding temperature close to 51 C (Figure 2A). The same process followed by 
fluorescence also showed a single transition with an apparent unfolding temperature close to 
48.5 C (Figure 2B). The small difference in the unfolding temperature could be justified by the 
use of a different protein concentration in CD and fluorescence assays and considering the 
oligomer-monomer equilibrium coupled to the unfolding process. Non-linear regression 
analysis of the unfolding traces according to different two-state models for a monomeric (n = 
1, see equation (1)), a dimeric (n = 2), a tetrameric protein (n = 4), and an octameric protein (n 
= 8) were performed (see Materials & Methods section). These experiments confirmed 3CLpro 
adopts a well-folded conformation under native conditions and becomes unstructured upon 
temperature stress. However, it was not possible to discriminate which model reproduces 
better the experimental data, because the fitting curves from the different models overlapped. 
The fitting was marginally better (according to the residual sum of squares; see Table S1) for 
the two-state monomer model in the case of CD unfolding, and for the two-state tetramer 
model in the fluorescence unfolding. Therefore, spectroscopic unfolding traces were not 
sensitive enough for discriminating the self-association nature of 3CLpro native state. 
Thermal unfolding monitored by differential scanning calorimetry (DSC) also showed a single 
apparent unfolding transition with a marked dependence on the pH (Figure 3A). The lower 
thermal stability observed at pH 5 and 8, compared to that at pH 7, may reflect the 
protonation/deprotonation equilibrium of ionizable sidechains titratable around pH 6-7 (e.g., 
histidines). Very importantly, the transitions are quite asymmetric, a clear indication of the 
oligomeric nature of the native state of 3CLpro. A model-free analysis (see Materials & 
Methods section) allowed to estimate an apparent unfolding enthalpy of 106 kcal/mol and an 
unfolding temperature of 54.2 C, at pH 8. Again, the difference in the unfolding temperature 
compared to those obtained by using spectroscopic techniques could be justified by the use of 
a different protein concentration in the DSC assays and considering the oligomer-monomer 













the van’t Hoff enthalpy and the calorimetric enthalpy was estimated to be > 1, which is 
another clear indication of the oligomeric nature of the native state of the protein. A small 
influence of the ionic strength of the solution on the thermal stability of the protein was 
observed (Figure S2A). The increase in NaCl concentration to 150 mM caused a reduction in 
the apparent unfolding temperature of 0.6 C, which suggested the uptake of salt ions upon 
protein unfolding. 
The scan rate along the DSC assay may distort the stability parameters (i.e., the DSC profiles 
may show a scan rate dependence) if the unfolding kinetic equilibration for the transitions 
between the conformational states is sufficiently slow. In this case, irreversible kinetic models 
should be applied instead of equilibrium models. In our experiments on SARS-CoV-2 3CLpro, a 
small scan rate dependence could be observed (Figure S2B). The data analysis according to the 
Lumry-Eyring model for protein thermal denaturation (Figure S2B, inset) allowed estimating a 
high kinetic activation energy barrier for the irreversible denaturation process, close to 200 
kcal/mol[29]. This energy barrier corresponds to a half-life for irreversible denaturation 
extremely long (close to 30 years at 37 C, and much larger at 25 °C). These results suggested 
the analysis employing equilibrium models may be appropriate. 
The two-state tetramer (n = 4) unfolding model reproduced significantly better the 
experimental data at pH 7 and 8 (Figure 3B), while the two-state dimer (n = 2) unfolding model 
reproduced better the experimental data at pH 5 (according to the residual sum of squares; 
see Table S1). Application of a more complex model considering the coexistence of tetramers 
and dimers (T  2D  4U) did not improve the results (Table S1). In addition, other models 
considering a two-step unfolding process where the dimeric or tetrameric states undergo a 
first transition with no dissociation (Nn  Nn*) followed by a second transition with coupled 
unfolding-dissociation (Nn*  nU) did not improve the results either. This indicates that any 
unfolding model considering more than one step lacks the sufficient cooperativity to 
reproduce the experimental results. Therefore, calorimetric unfolding traces were sensitive 
enough for discriminating the self-association nature of 3CLpro native state, and very likely 
there is a pH dependence of the quaternary rearrangement in 3CLpro. 
 
SARS-CoV-2 3CLpro activity profile correlates with the thermal stability profile 
The enzymatic activity of 3CLpro was measured using a FRET substrate containing 
Edans/Dabcyl as the donor/acceptor FRET pair. Continuous assays allowed us monitoring the 
time evolution of the substrate fluorescence emission as a function of time at different pH 













correlates with the pH dependence of the structural stability observed by DSC assays. Among 
other factors, the pH dependence of the enzyme activity may reflect structural changes (either 
secondary, tertiary or quaternary, or a combination of them) and, very importantly, the 
ionization state of titratable sidechains from the catalytic dyad residues (Cys-145 and His-41). 
Very likely, the catalytic histidine is responsible for this pH effect. 
The enzymatic parameters were estimated from the initial enzymatic rate dependence on the 
substrate concentration at pH 8 (Figure S3): Km = 11 M and kcat = 0.040 s
-1, resulting in a 
catalytic efficiency, kcat/Km of 3640 M
-1 s-1, comparable to reported values considering the 
differences in the experimental conditions[21, 22]. 
 
Screening of a small chemical library 
The continuous FRET assay for measuring the activity of 3CLpro was adapted to an in vitro 
experimental screening procedure. In a first step, the screening was performed using a small 
chemical library consisting of 150 compounds, which also included approved drugs with known 
therapeutic indications. Hits consisted of compounds reducing the enzymatic activity of 3CLpro 
below a specified threshold, defined as the average activity for the controls (enzyme with no 
compound) minus twice their corresponding standard deviation (Figure 5). Several hits were 
selected and confirmed by the inhibition curve analysis. 
 
Quercetin inhibits SARS-CoV-2 3CLpro in vitro 
To assess the in vitro potency of the compounds selected through the small-scale screening, 
their inhibition constants was estimated from the inhibition curve. Inhibition curves were 
obtained by measuring the enzymatic activity, applying the previously described protocol for 
the continuous FRET assay, by fixing the enzyme and the substrate concentrations while 
varying the amount of compound (Figure 6A). Enzymatic activity at each compound 
concentration was calculated as the initial slope in each curve, and a dose-dependent effect of 
the compound on the enzyme activity was observed (Figure 6B). Non-linear regression analysis 
employing a simple inhibition model, according to equation (10) (see Materials & Methods), 
allowed estimating an apparent inhibition constant, Ki
app, of 21 M for quercetin, the most 
active compound. Because it can be assumed this compound might bind to the active site, 
thus, functioning as a competitive inhibitor, this apparent inhibition constant can be 
transformed into an intrinsic inhibition constant according to: Ki = Ki
app/(1+[S]/Km), or, 
equivalently, the fitting can be carried out using equation (11), which accounts for competitive 
inhibition and the substrate concentration and Km appear explicitly (see Materials & Methods). 













constant Ki of 7.4 M could be estimated for quercetin. This potency is similar to some of the 
first inhibitors found for SARS-CoV 3CLpro[30]. 
 
Quercetin affects SARS-CoV-2 3CLpro thermal stability 
In general, the interaction of a ligand with a protein results in a change in the stability of the 
protein against thermal or chemical denaturation. More precisely, the preferential interaction 
of the ligand with certain conformational state stabilizes that state, resulting in a net global 
stabilization effect if the preferential interaction occurs with the native state or a net 
destabilization if the preferential interaction occurs with the non-native state. Thermal shift 
assay (TSA), also called differential scanning fluorimetry, consists in detecting ligand-induced 
stability changes in proteins by fluorescence[31, 32]. Using an extrinsic fluorescent probe 
reporting the progression of the protein unfolding process, it is p ssible to assess the thermal 
stability of the protein by measuring its apparent Tm in the presence of increasing 
concentrations of a given interacting compound. 
The identified compound, quercetin, altered the thermal stability of 3CLpro causing a 
destabilization (Figure 7A). Although ligand-induced stabilizing effects on a protein are more 
common, it is not unusual to observe destabilizing effects[33-35]. In addition, the effect of the 
compounds was concentration-dependent (Figure 7B). 
 
Quercetin interacts with SARS-CoV-2 3CLpro 
Isothermal titration calorimetry (ITC) is considered the gold-standard for binding affinity 
determination, as well as target engagement in drug discovery[36, 37]. Careful experimental 
design in ITC provides invaluable and detailed information about the drug-target 
interaction[38]. ITC was employed to assess target engagement for quercetin and get a direct 
estimation of the dissociation constant for its interaction with 3CLpro. According to the 
experiments, quercetin interacts with 3CLpro with a dissociation constant of 2.7 M in the 
absence of NaCl, and a dissociation constant of 10 M in the presence of NaCl 150 mM (Figure 
8), in good agreement with the inhibition constant estimated through the inhibition curve 
(which was determined in the presence of NaCl 150 mM). 
 
Quercetin binds to SARS-CoV-2 3CLpro active site 
Molecular docking was used to clarify the interaction of quercetin with 3CLpro. Two 
crystallographic structures were considered, corresponding to the protein in unliganded form 
or with an inhibitor bound in the active site, reported as entry 6Y2E and 6Y2F in the PDB[22], 













quercetin. For both molecular receptors, the most favorable binding modes predicted through 
a blind search carried out on the whole protein surface were found in the known protein active 
site. The binding affinity ranged from -7.5 to -7.2 kcal/mol, corresponding to a dissociation 
constant of  3-5 µM, in reasonably good agreement with the value obtained experimentally 
(Kd of 2.7 µM). A variety of slightly different binding modes were obtained, all distributed in 
the same binding location. This observation is consistent with the pseudo-symmetric chemical 
structure of quercetin, with five hydroxyl groups determining a number of possibilities in the 
formation of hydrogen bonds as donors.  
As detailed in the Figure 9 (see Insets b and c), the two binding modes of quercetin most 
distant from each other still occupied the same protein crevice. In particular, they mostly 
overlapped with the position of a single larger known ligand, the α-ketoamide inhibitor co-
crystallized with 3CLpro in the PDB entry 6Y2F[22]. Interactions with a number of protein 
residues contribute to bind quercetin into the 3CLpro binding site. The key residue is Met165, 
which can form both hydrogen bonds and hydrophobic interactions with quercetin. Additional 
hydrogen bonds can be formed with the two residues Ser144 and Met165. Energetic 
contributions are also due to supplementary hydrophobic interactions with Met49, Phe140 
and Leu141, and to electrostatic interaction formed with the polar residue His164 and the 
charged residue Glu166. 
 
DISCUSSION 
The need for pharmacological agents acting against SARS-CoV-2 is urgent. The development of 
drugs acting through different mechanisms provides a good starting point for a combined use 
in a therapy with low susceptibility to drug resistance. 3CLpro (or Mpro) is an appropriate 
target, given its high conservation among coronaviruses, as well as a suitable experimental 
tractability and druggability. Drug discovery can be initiated from experimental or 
computational screenings, by employing small or large, highly diverse or focused (target-
derived) chemical libraries. On the basis of an experimental pipeline for drug screening 
successfully employed in the past[35, 39-45], we have applied the same methodology to 
identify small molecules blocking the activity of SARS-CoV-2 3CLpro. 
The first step in this screening program was to assess the stability and the in vitro activity of 
SARS-CoV-2 3CLpro. According to our results, 3CLpro is well folded in solution and exhibits a 
large kinetic stability (activation energy barrier  200 kcal/mol), which allowed us to apply 
equilibrium models for unfolding. It has been established that monomeric 3CLpro is 
inactive[46] and the functional state of this protein is the homodimer. We observed that 













the pH. Interestingly, even tetrameric and highly-active octameric states have been previously 
reported for 3CLpro[22, 27]. In addition, the effect of pH on the structural stability parallels 
that of the enzymatic activity, suggesting some titratable residues in the range of pH 5-8 are 
instrumental to guarantee both these properties. Hydrodynamic radius measurements by 
dynamic light scattering showed a predominant population of particles compatible with 
dimeric 3CLpro (hydrodynamic radius of 3.89, 3.33, and 3.94 nm at pH 5, 7, and 8, 
respectively), with an expected smaller size around its isoelectric point (pI  6) due to smaller 
net charge and lower electrostatic repulsions (Figure S4). Additional experiments using size-
exclusion chromatography were also in agreement with a predominantly dimeric 3CLpro 
(Figure S4). It may be hypothesized that, along the thermal denaturations, temperature could 
trigger a transient dimerization of dimers into tetramers (tetrameric intermediate) at 
moderate temperatures, a temperature-driven oligomerization process that has been 
observed in other proteins[47, 48], before reaching the unfolding temperature and ending in 
monomer unfolding/dissociation; work on this matter is in progress. 
The screening test for 3CLpro could be based on detecting small molecules interfering with the 
enzymatic activity (which it is fairly easy for a protease, by using a continuous enzymatic assay 
and a peptidic FRET substrate) or based on detecting the effect of small molecules on altering 
the thermal stability of the protein against thermal denaturation (by using fluorescence TSA). 
The TSA-based screening has the advantage of being quite general for any protein, but it has 
some disadvantages: 1) binding affinity does not correlate with stability changes; 2) false 
negatives are somewhat common, because ligands may bind to unfolded or non-native protein 
states besides binding to the native state; 3) stability changes are highly dependent on the 
binding enthalpy and binding heat capacity; and 4) the ligand binding does not always 
translates into an inhibitory effect[49]. In contrast, the techniques based on detection of the 
protein activity provide direct evidence for inhibition during the screening test, but the activity 
of the protein target must be measurable through a quick and appropriate procedure, which is 
not straightforward in general. 
Through the application of a small-scale activity-based screening to SARS-CoV-2 3CLpro, the 
quercetin was selected and further studied. Direct evidence for target engagement was 
gathered by different biophysical techniques, TSA and ITC, as well as through molecular 
docking simulations. Quercetin showed an inhibition constant of about 7 µM, which 
corresponds to a binding affinity sufficiently favourable to be considered as a good candidate 
for optimization or preclinical studies. 
The fact that quercetin exerts a destabilizing effect may be related to its physico-chemical 













effect induced by a ligand depends on the specific set of conformational states, within the 
whole conformational landscape of the protein, that interact preferentially with the ligand. If 
the ligand interacts with most of the conformational states with similar binding affinities, the 
effect on the protein stability will be small. If the ligand interacts not only with the native state, 
but also with partially unfolded states (which could be the case for quercetin, due to its 
hydrophobic moiety), a destabilization effect could be expected if the affinity (or the binding 
stoichiometry) for the non-native states is higher. These are some of the caveats (described 
above) to be born in mind when TSA is applied for in vitro molecular screening. In addition, 
unlike in the case of isothermal inhibition assays, where only native-like states are accessible, 
through TSA it is possible to gradually explore non-native states close to the native state 
through a temperature-driven process, and binding to non-native states can be detected. In 
any case, regardless of whether the effect of the ligand on the protein was destabilizing or 
stabilizing, quercetin interacted and inhibited the activity of 3CLpro. 
The influence of quercetin on the structural properties of 3CLpro was assessed (Figure S5), and 
provided an additional piece of evidence for the interaction of quercetin with 3CLpro. The far-
UV CD spectrum of the protein was not significantly distorted by quercetin, but considerable 
changes occurred in the near-UV CD and fluorescence spectra. In particular, a substantial 
decrease in tryptophan fluorescence could be observed in 3CLpro upon quercetin binding. 
Very likely these alterations in the tertiary structure of the protein are associated with the 
destabilizing effect of quercetin on the thermal stability of 3CLpro observed by TSA. 
According to ITC experiments, quercetin binds with favorable enthalpic (H = -3.6 kcal/mol) 
and entropic (-TS = -4.0 kcal/mol) contributions to the Gibbs energy of binding (G = -7.6 
kcal/mol). The hydrophobicity, the compactness and the rigidity of the molecule, and the 
ability to adopt multiple configurations within the binding site seem to be responsible for a 
large desolvation entropy gain and small conformational, configurational and roto-
translational entropy losses upon binding, resulting in a global favorable entropy gain. 
Quercetin would be an appropriate scaffold to engineer new functional groups for developing 
new inhibitor compounds for SARS-CoV-2 3CLpro. The lower affinity at high ionic strength 
(Figure 8) indicates that the binding of quercetin to 3CLpro is coupled to the release of salt 
ions. 
Quercetin compares quite well to SARS-CoV-2 3CLpro inhibitors already reported. An intrinsic 
inhibition constant Ki of 0.19 M could be estimated for an alpha-ketoamide inhibitor 13b 
reported by Zhang et al[22]. In order to compare the inhibition potency of ligands, their 
molecular size must be considered. The ligand efficiency or binding efficiency index (BEI = 













Because quercetin and inhibitor 13b have a MW of 0.302 kDa and 0.598 kDa, respectively, 
their ligand efficiencies are 17.0 and 11.2, respectively. Thus, although the alpha-ketoamide 
inhibitor has a much lower inhibition constant, which is not surprising given its larger MW of 
the alpha-ketoamide inhibitor; in fact, quercetin is close to be considered as a fragment (MW < 
300 Da) from a screening perspective. However, BEI is significantly higher for quercetin, 
suggesting it is a good candidate establishing good interactions with the target and possessing 
high potential for optimization and development. 
It is worth to note that quercetin is a natural product with well-known pharmacokinetics and 
ADMET properties and some proposed therapeutic indications, which points to a potential 
repurposing for COVID-19 treatment. Interestingly, and in agreement with our blind assays, 
experimental evidences had been reported in the past for an inhibitory effect of quercetin on 
the 3CLpro from the coronavirus variant MERS-CoV[51]. The work presented here provides a 
direct evidence for quercetin ability to target SARS-CoV-2 3CLpro on solid experimental bases. 
Furthermore, it represents a successful starting point that guarantees the possibility to extend 
our experimental approach for identifying SARS-CoV-2 3CLpro drug candidates to larger 
chemical libraries, in order to find small molecules to be used (or further optimized) as 
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Figure 1. Spectroscopic properties of SARS-CoV-2 3CLpro. (a) Far-UV CD at 10 µM protein 
concentration. (b) Near-UV CD at 10 µM protein concentration. (c) Fluorescence at 2 µM 
protein concentration. All the spectra were recorded at pH 8. 
 
Figure 2. Spectroscopic thermal unfolding of SARS-CoV-2 3CLpro. (a) Far-UV CD thermal 
unfolding monitoring the (raw) ellipticity at 222 nm, at 10 µM protein concentration. (b) 
Fluorescence thermal unfolding monitoring the intrinsic tryptophan fluorescence emission at 
330 nm, at 2 µM protein concentration. Both experiments were recorded at pH 8. The 
experimental data (circles) and the non-linear regression analysis fitting curves (continuous 
lines) according to two-state monomeric, dimeric and tetrameric protein are shown 
(indistinguishable in the plot). 
 
Figure 3. Calorimetric thermal unfolding of SARS-CoV-2 3CLpro. (a) Molar excess heat 
capacity as a function of temperature at pH 5 (black), pH 7 (red), and pH 8 (green), at a 14 µM 
protein concentration. (b) Molar excess heat capacity as a function of temperature at pH 8. 
The experimental data (circles) and the non-linear regression analysis fitting curves 
(continuous lines) according to two-state monomeric (gray), dimeric (green), tetrameric (red), 
and octameric (blue) protein unfolding models are shown. 
 
Figure 4. Catalytic activity of SARS-CoV-2 3CLpro. Time evolution of the substrate 
fluorescence emission as a function of time at pH 5 (black), pH 7 (red), and pH 8 (green), at 
protein concentration of 1 µM and substrate concentration of 20 µM. The increase in 
fluorescence emission reflects the decrease in Dabcyl quenching on Edans emission (i.e., 
reduction of FRET phenomenon) due to the increase in the spatial separation of the donor-














Figure 5. Screening of a small chemical library. Enzyme activity, in the presence and the 
absence of compound, was quantitated as the initial slope of the fluorescence emission as a 
function of time. Control wells (red squares) contained enzyme and substrate in the presence 
of an identical concentration of DMSO as that in the wells with compounds (black squares). 
Hits were selected as those compounds lowering the activity below a certain threshold 
(average activity of controls minus twice the standard deviation of those controls, lower 
dotted line). The blue square corresponds to quercetin. 
 
Figure 6. Hit confirmation through inhibition curve. (a) Substrate fluorescence emission as a 
function of time, fixing the enzyme concentration at 2 µM, the substrate concentration at 20 
µM, and varying quercetin concentration from 0 to 125 µM (while maintaining constant the 
percentage of DMSO). The increase in quercetin concentration resulted in the decrease in the 
enzymatic activity. (b) Experimental inhibition data for quercetin (squares), together with the 
non-linear regression analysis fitting curve (black line) to a simple inhibition, from which the 
apparent inhibition constant (Ki
app = 21 M) or the intrinsic inhibition constant (Ki = 9.6 M) 
could be estimated. 
 
Figure 7. Hit confirmation through thermal shift assay (TSA). (a) Unfolding traces of the 
compound-free protein (black) and the protein in the presence of 62.5 µM quercetin (red). (b) 
Apparent unfolding temperature for the protein at different quercetin concentrations. 
 
Figure 8. Hit conformation through isothermal titration calorimetry (ITC). Interaction of 
quercetin with 3CLpro assessed by isothermal titration calorimetry in sodium phosphate 50 
mM, pH 8, without (left) and with (right) NaCl 150 mM. The upper plot shows the thermogram 
(thermal power required to maintain a null temperature difference between sample and 
reference cells as a function of time) and the lower plot shows the binding isotherm (ligand-
normalized heat effect per injection as a function of the molar ratio, the quotient between the 
ligand and protein concentrations in the cell). The fitting curve corresponds to the single ligand 
binding site model (continuous line). According to the data analysis, in the absence of NaCl 
quercetin interacts with 3CLpro with favorable enthalpic (H = -3.6 kcal/mol) and entropic (-
TS = -4.0 kcal/mol) contributions to the Gibbs energy of binding (G = -7.6 kcal/mol), 
corresponding to a dissociation constant Kd of 2.7 M. In the presence of NaCl quercetin 













kcal/mol) contributions to the Gibbs energy of binding (G = -6.8 kcal/mol), corresponding to a 
dissociation constant Kd of 10 M. In both cases, the percentage of active (or binding-
competent) protein is 0.75. 
 
Figure 9. Molecular docking of quercetin to 3CLpro. Structure of (a) unliganded 3CLpro (from 
entry 6Y2E of the PDB; in ribbon representation, yellow) and α-ketoamide inhibitor bound in 
the active site (from entry 6Y2F; in stick representation, yellow)[22]. The liganded protein was 
superimposed by a least square fit on the Cα atoms of the liganded one, and only the latter is 
shown. (b) and (c) Detail of the 3CLpro active site, with the two best docking poses obtained 
using as receptor the structure 6Y2E (cyan) and 6Y2F (purple). Polar hydrogen atoms are 
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HIGHLIGHTS 
 SASR-CoV-2 3CLpro shows cooperative unfolding in which dimers or tetramers 
predominate depending on the pH. 
 SARS-CoV-2 3CLpro shows a pH-dependent hydrolytic activity that correlates with its 
structural stability. 
 SARS-CoV-2 3CLpro is an appropriate target for drug discovery given its high sequence 
identity among different coronaviruses. 
 Quercetin has been identified as a SARS-CoV-2 3CLpro inhibitor by an activity-based 
experimental screening. 
 Experimental and computational evidences for quercetin target engagement have 
been obtained by ITC, spectroscopy, TSA, and molecular docking. 
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